AstraZeneca Pharma India has received Import and Market Permission in Form 45 (Marketing Authorization) from the Drug Controller General of India (DCGI) for FDC of Dapagliflozin + Metformin Hydrochloride (Extended Release) film coated tablets (XIGDUO XR).
The FDC of Dapagliflozin + Metformin Hydrochloride (Extended Release) film coated tablets (XIGDUO XR) is indicated as an ajunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.